Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
Finch Therapeutics Announces Additions to Senior Leadership Team
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
